docsetc
1 day ago
Yeah, I was amazed at how long it took for Theranos and their financial backers, which included Yahoo, to kick her to the curb. The evidence of downside was everywhere from day 1. (Kinda' like Harry Z.)
Chandra exhibits some of the same bad habits and business decisions that Harry did. He "might" just be an AI genius and medical applications expert, but his business acumen, professional interaction and his unwillingness to get his hands dirty with some honest work, bother the hell out of me. A lot of us gave him a second chance, but now he's bucking for "3 strikes and you're out!"
Anyway, if Charles accepted and read the letter, he knows he has a nice way out of this, one that should help Andexus launch far larger than what they could do alone, without the deal we're offering. Even sadder, they may not be smart enough to even consider that option.
GLTY
docsetc
3 days ago
LOL, you never know. Holmes was known as a mindless idiot fraud when Yahoo first bragged about her ascension to top-dawg spot at Theranos. I bet my friends on that, what about 7 years ago now, that she'd come crashing down. We all just had a dinner and drinks at a nice steakhouse over that one 3 weeks ago. I finally collected my free dinner and drinks.
We have a similar bet going on now about how some Apple higher ups will be getting demoted by end of 2026. Collecting on these bets can take some time.
Charles has some possible 'outs' if we get to take him to trial. So, the lawyers currently reviewing the case are going over those with a fine-toothed comb, in telling us whether or not they or another class-action firm would take the case. But we would get a hearing and probably win that, to go to trial, they are telling me. They said the probable cause, standing and a little gray area about some legal mandates in a case like this, leave it wide open for a judge not to deny a motion to go to trial.
And there's a lot of pressure that would be dumped hard upon CCC and Adnexus/CBDW as a whole, not to mention GHS Investments, if this goes to trial. It could cost them their new partner and that partner's stake money.
We'll see.
docsetc
4 days ago
Hey Dog, here's the breakdown you asked for.
It was pretty disappointing. I saw a couple of pumpers on Twitter talking about a 'few nuggets' in the short call, and I refute that with simple facts.
1) Lambrecht & Co refused to give even a hint of what percentage of Adnexus Biotech would be owned by CBDW, or how much would be invested in the ex-ENZC operation under CCC. He claimed, only at the time of closing and making the investment official, would any such details about their 'significant stake' be revealed to the public.
2) He suggested, anyone who wants involvement in Adnexus "probably needs to buy CBDW stock now".
3) He said he does not know if Adnexus Biotech plans to go public, "go ask them" was his response. Now, anyone who knows an LOI for large investment capital funding, knows full well, the funding party knows all of the plans for future and especially near-future financial plans of the target they are acquiring a 'significant stake in." This one is a lie, unless GHS Investment Partner's are keeping the junior Lambrecht in the dark. Somehow, I don't think so.
4) Lambrecht went into presenting his AI Chatbot product in detail, not much new to see there, all tech that's been done before, and if they have something really innovative and new, it failed to come across clearly. Keep in mind, I work with some of the best AI products around.
5) Seemed like all 7-8 of the questions pertained to Adnexus Biotech, and some financial planning of CBDW's (1 question) finances. The room kinda' went dead when no one else had more questions to pose to them, and many folks were on the call. They limited participant visibility, so they are worried about too many details getting out too early.
It all smelled of more possible delays and added credence to the rumor that $CBDW may turn into $ADNX outright. This would be taking Adnexus public in a wide-roundabout way. Personally, I don't see AI - Education about CBD to be very popular. Cannabis uses and desires by the public seem to be at an all-time low since many states legalized cannabis use. About 91% of most Cannabis stocks have failed on the market, some barely hanging on. The ones still making any money at all are corporate-for-medical-use Cannabis operations, and they are not 'raking it in' either. Having a PC sell you on using Cannabis via an AI discussion, just does not seem like anyone's priority. Simply, I don't see that demand much at all.
That being said, Lambrecht can probably make his AI product profitable, promised a lot of new customers about to launch their websites into it, but nothing was working well enough to show anyone yesterday, "technical issues being worked out" he said.
1606 Corp, CBDW has been at this for 2+ years now as a company and a couple years before that, so that statement of his was not confidence inspiring. Company employment sheet only shows Lambrecht and one other programming engineer at CBDW currently.
Their main funder, GHS Investments, not their parent, SinglePoint, is where the money has to come from to buy into or acquire Adnexus. If the deal does close and Adnexus gets the funding, you can be pretty sure they have the goods, because GHS will probably vet them well. Lambrecht indicated a serious interest in Chandra's AI, but also mentioned the mABS products a couple of times. If the deal does not close, you can bet Clone3/7 were faked or not developed well enough in either case. If they do get funded, my gut tells me all of Chandra's hints and promises about what was coming, are for real and probably just months off his projected deadline dates again. Money arrives to Adnexus, then the mABS and the AI are all working very well. (My thoughts on the Adnexus validity)
Personal opinion: My gut's also telling me, that CCC is probably selling off a majority stake in Adnexus, not a minority one like they should, having been through the Harry Z era and contributing to ENZC's overall failure. I think they want the easy way out. I believe they'll be given limited autonomy to run things any way they want, unless profit potentials plummet, and GHS has to appoint a new CEO. If the mABS, new licensing partners and trial efforts do work, and the AI does sell like Chandra says it will, he'll probably be CEO of Adnexus forever. But I bet the CFO, COO and other corporate stuff he'll leave for CBDW-GHS Investment assigned staff to handle. (Happily, too).
I think with the CCC board members aging out, if you will, and only Chandra, Joe Cotropia and the Sanctum bioengineers left as the mABS and AI core experts in what may be a growing Adnexus venture, keeping say a 40-45% interest in Adnexus, as they had in ENZC, looks lucratively attractive to them right now. Even if they just drive up a stock spike to say $2.00 pps, for the entire thing, their share count would land more millions on them, for a lot less work and stress.
This is only a personal opinion, based in part on my gut warnings to be eyes-wide-open, the CCC player's repeating history, attractive terms of what would close GHS Investments fast during Chandra's Summer Trip to Seattle, where Sanctum introduced him to GHS Investments, and the priorities needed to get Adnexus off the ground and moving. I just get a buzzing in the back of my brain to expect this scenario to come out. If GHS only takes a minority stake, I'll bet its high, like around 48% of the company, just to make a full acquisition later an easy task to accomplish.
That's it, GLTY!
docsetc
5 days ago
Buyers in ENZC after April of 2024 may be screwed to some point, maybe not, depends upon what, if anything comes from this legal motion. Most buyers after May, if they did their own DD, don't have much of an excuse for buying into a seriously troubled PINK stock, unless they did it based upon implied promises from Chandra. (courts will have to hear about those cases). There was information everywhere about what ENZC trouble was brewing strong in an OTC:PINK stock that was restructuring completely, allegedly, their story changed several times in PR's alone. No sane person would have invested, so for those who keep buying the stuff, for whatever reason, really have no complaint about being defrauded except for the published Lies in their PRs. The SEC has chosen to ignore those for the time being.
SAFE not holders may not be so screwed. Their portions of the case are tied directly to CCC, and to their known business practices that helped lead to the defrauding of shareholders. We'll have to see Cotropia's response.
GLTA